Epigenetic therapy reverting aberrant acetylation or methylation offers the possibility to target preferentially tumor cells and to preserve normal cells. Combination epigenetic therapy may further improve the effect of individual drugs. We investigated combined action of demethylating agent decitabine and histone deacetylase inhibitor SAHA (Vorinostat) on different leukemic cell lines in comparison with peripheral blood lymphocytes. Large decrease of viability, as well as huge p21WAF1 induction, reactive oxygen species formation, and apoptotic features due to combined decitabine and SAHA action were detected in leukemic cell lines irrespective of their p53 status, while essentially no effect was observed in response to the combined drug action in normal peripheral blood lymphocytes of healthy donors. p53-dependent apoptotic pathway was demonstrated to participate in the wtp53 CML-T1 leukemic cell line response, while significant influence of reactive oxygen species on viability decrease has been detected in p53-null HL-60 cell line.

• MeSH
• apoptóza účinky léků   MeSH
• azacytidin aplikace a dávkování   analogy a deriváty   MeSH
• decitabin MeSH
• kultivované buňky MeSH
• kyseliny hydroxamové aplikace a dávkování   MeSH
• leukemie farmakoterapie   patologie   patofyziologie   MeSH
• lidé MeSH
• lymfocyty cytologie   účinky léků   fyziologie   MeSH
• protinádorové antimetabolity aplikace a dávkování   MeSH
• protokoly protinádorové kombinované chemoterapie aplikace a dávkování   MeSH
• vorinostat MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• azacytidin MeSH
• decitabin MeSH
• kyseliny hydroxamové MeSH
• protinádorové antimetabolity MeSH
• vorinostat MeSH